Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

PFE) stands against other best affordable stocks to invest in. The broader market has taken a significant hit, dropping 10% ...

Pfizer (PFE) is one of the stocks most watched ... No investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic ...

At present, Healthcare’s dividend yield is 7.3% at 31 cents per share. Over a year, HR stock is up nearly 20%, effectively ...

Pfizer (PFE) is one of the stocks most watched ... Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial ...

Pfizer (PFE) is one of the stocks most watched ... This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.